A recent study found that treatment with ICG-001, a molecule that can impair the WNT/β-catenin signaling pathway [64], has strong anti-cancer activity against uveal melanoma by inhibiting the expression of EMP1 and the mTOR and mitogen-activated protein kinase (MAPK) signaling pathways [65]. The gene discussed is EMP1; the disease is cancer.